SINGAPORE, Dec. 12, 2025 /PRNewswire/ — Kuailu Tech today announced a significant upgrade to its Kuailu Cloud AI-CRM platform, introducing a new generation of AI-driven capabilities designed to help small and mid-sized manufacturers (SMEs) modernise customer management, automate sales operations, and improve sales-to-production coordination across Southeast Asia.
The enhanced platform addresses core challenges faced by manufacturers in Singapore, Hong Kong SAR, Malaysia, Thailand, and Vietnam, including fragmented customer data, manual follow-up processes, and limited visibility across distribution and production activities. With the latest release, Kuailu Cloud AI-CRM strengthens its position as one of the region’s most complete manufacturing-focused CRM solutions, offering rapid deployment without the cost or complexity of traditional enterprise systems.
New AI Capabilities Purpose-Built for Manufacturing
The upgrade delivers deeper intelligence, automation, and collaboration across the full customer lifecycle. Key enhancements include:
360° Unified Customer Intelligence consolidating real-time data from distributors, OEM partners, service teams, and end customers into a single, actionable view.
AI-Enhanced Sales Automation providing predictive pipeline forecasting, automated follow-up reminders, and efficiency tools that support faster, more reliable sales execution.
Proven Business Impact for Early Adopters
Manufacturers across precision engineering, industrial components, metal fabrication, and consumer goods have already recorded significant operational gains with the enhanced AI-CRM:
40% increase in repeat purchase rates
60% reduction in service-related operational costs
Up to 85% faster sales-to-production coordination
Customer churn consistently below 8%
“These results highlight the transformative potential of accessible, AI-driven systems for the manufacturing sector,” said Kuailu Tech’s Product Strategy Lead. “SMEs across Southeast Asia often operate with limited digital infrastructure. Our upgraded AI-CRM offers a powerful, easy-to-adopt platform that delivers measurable improvements within weeks.”
Flexible, Localised, and Designed for Real Manufacturing Workflows
Kuailu Cloud AI-CRM supports the end-to-end operational needs of modern manufacturing businesses with:
Low-code configuration enabling rapid adaptation to regional workflows and compliance requirements
Multi-device access for sales, service, and factory teams operating across multiple sites
Seamless integration with ERP, production management, and supply chain systems
The enhanced Kuailu Cloud AI-CRM is now available to all new and existing customers, supported by Kuailu Tech’s regional onboarding and migration teams.
Request a Demo Manufacturers looking to strengthen customer lifecycle management, improve sales automation, or accelerate sales-to-production workflows can request a demo via sales@kuailutech.com.
About Kuailu Technology (HK) Limited
Kuailu Tech is a global AI technology company dedicated to enabling intelligent digital transformation. Powered by proprietary large-model AI, the company offers a unified ecosystem that includes AI smart office solutions, AI collaboration tools, intelligent meeting systems, workflow automation, AI-driven CRM, low-code customisation, and ERP integration. Kuailu Tech helps organisations operate with greater speed, efficiency, and accuracy. For more information, visit www.kuailutech.com.
A heart disease patient from Laos receives color Doppler ultrasound check at Yunnan Fuwai Cardiovascular Hospital. (photo: Yang Jinghao)
Laos has introduced a nationwide program aimed at improving the detection and treatment of congenital heart disease among children, marking one of the country’s most comprehensive health initiatives in recent years.
The Mekong Children’s Heart Care Project (2025–2027) was launched in Vientiane through a partnership between the Ministry of Health, the Mekong Institute, and Fuwai Hospital of the Chinese Academy of Medical Sciences.
Supported by financing from the Global Development and South–South Cooperation Fund, the project is part of broader regional efforts under the Global Development Initiative to reduce preventable childhood deaths and expand access to specialized medical services.
Large-Scale Screening and Skills Development
The program aims to build a national system for the early detection of congenital heart defects, a leading cause of child mortality in Laos and Cambodia. Over the next two years, at least 10,000 children are expected to be screened across urban and rural areas. Children diagnosed with heart defects will receive full-cycle treatment, with a minimum of 30 cases targeted during the implementation period.
A key component of the project focuses on workforce development. More than 110 Lao healthcare professionals will undergo specialized training, while selected medical staff will participate in fellowship programs at Fuwai Hospital. Medical equipment,including an ultrasound machine,will be distributed to strengthen diagnostic capacity at provincial hospitals.
The launch marks an expansion of cross-border health cooperation in the Mekong region. The project is designed not only to improve clinical outcomes for children in Laos but also to establish a shared technical framework that benefits neighboring Cambodia. Coordinated efforts between national agencies and regional institutions are expected to enhance long-term service delivery and contribute to UN Sustainable Development Goal targets related to child mortality.
Building on Prior International Initiatives
The new program follows a series of successful cross-border collaborations in pediatric heart care. In 2024, a Laos–Thailand partnership enabled dozens of Lao infants to access free cardiac surgeries in Thai hospitals, with screening and referrals coordinated by Nong Khai Hospital and specialist institutions in Bangkok.
Earlier, in late 2023, several Lao children were sent to Kunming under the “Love Heart Journey” initiative, a cooperation effort between Chinese charitable organizations, the Yunnan provincial government, and Yunnan Fuwai Cardiovascular Hospital.
These programs demonstrated the benefits of targeted international support and underscored the need for a more sustainable, nationally led system, an objective the newly launched Mekong Children’s Heart Care Project aims to meet.
Long-Term Vision
Authorities expect the new project to play a central role in shaping Laos’ future policy direction in pediatric cardiac care. By creating standardized screening pathways, expanding treatment access, and improving data collection, the initiative is intended to strengthen the national health system well beyond its three-year implementation timeframe.
Rollout activities involving provincial health departments, schools, and local hospitals are scheduled to begin immediately, with the aim of reaching remote communities where access to specialized care remains limited.
MELBOURNE, Australia, Dec. 12, 2025 /PRNewswire/ — Bizcap, one of the fastest-growing alternative lenders, has promoted Rebecca del Rio to Deputy CEO for Asia-Pacific, recognising her substantial contributions to the company’s growth and evolution since joining at its inception in 2019. Del Rio will also continue in her existing capacity as Global Chief Revenue Officer, driving the organisation’s global revenue strategy.
Rebecca del Rio has been promoted to Deputy CEO for Bizcap APAC
Over the past six years, del Rio has grown alongside Bizcap, taking on an increasingly expansive leadership role. Her remit spans marketing, sales, partnerships, people and culture, analytics, innovation, and product – a breadth of responsibility that positions her strongly to help steer Bizcap’s next phase of strategic development.
Since its inception, Bizcap has funded $4.8 billion globally, including $1.5 billion in 2025 across Australia, New Zealand, Singapore, the UK, Europe, the US and Canada. The company’s rapid momentum is reflected not only in its expanding footprint but also in its growing workforce, with global headcount rising more than 80% year-on-year.
As Bizcap has expanded into new markets and scaled its operations internationally, del Rio’s portfolio has broadened accordingly, giving her deep insight into the company’s business functions across regions including Australia, New Zealand, Singapore, the UK, Europe and Canada.
Del Rio’s promotion complements Bizcap’s collaborative leadership model, which brings together operational expertise from Global Chief Operating Officer Adam Szental, credit and risk leadership from Chief Credit Officer Tony Truong, and the strategic direction set by co-founders Zalman Blachman, Abrahram White and Albert Gafhi. This strengthened alignment positions Bizcap to execute its growth plans with greater cohesion and clarity.
Bizcap’s Co-Founder and Co-CEO Zalman Blachman said that del Rio’s leadership has been foundational to Bizcap’s trajectory, acknowledging her impact and the respect she commands across the organisation.
“Rebecca has played a significant role in Bizcap’s journey and growth. Her commitment, expertise, and collaboration with our broader leadership team have helped shape who we are today. We’re excited to see her continue contributing to our collective success in this next chapter,” Blachman said.
Abraham White, Bizcap’s Co-Founder and Co-CEO, reflected on del Rio’s contribution to Bizcap’s culture and strategic direction, emphasising her vision and relentless drive.
“It has been a privilege to see Rebecca’s vision and dedication contribute to Bizcap’s culture and strategic direction. She brings an energy that strengthens our leadership team, and I’m looking forward to all that’s ahead,” White said.
In accepting the promotion, del Rio expressed her enthusiasm for the opportunity to help shape the company’s future.
“I’m honoured to step into the role of Deputy CEO for APAC. Having grown with Bizcap from day one, I’m deeply passionate about our mission, as well as our partners and customers. I’m incredibly grateful to have the trust of our founders, executive team and global partners to support the next stage of Bizcap’s growth and innovation,” she said.
As Bizcap accelerates its international expansion, del Rio’s elevated role provides strong leadership at a pivotal moment, positioning the organisation to scale responsibly and cohesively across global markets.
Patient survey finds that those engaged in shared decision-making were 11 times more likely to report higher satisfaction with their treatments, with 90% of lung cancer patients in Japan wanting to play an active role in their treatment decisions[1]
J&J deepens its commitment to patient empowerment in Asia Pacific by launching J&JwithMe, a new patient portal offering tailored patient resources, and co-driving market-specific initiatives with patient advocacy groups
SINGAPORE – Media OutReach Newswire – 11 December 2025 – Johnson & Johnson announced the next phase of The 3rd Opinion campaign across Asia Pacific, focused on championing shared decision-making between lung cancer patients and healthcare professionals through events and stakeholder engagements at ESMO Asia 2025 in Singapore.
At a Patient Reception on 6th December 2025, 20 leaders from 17 patient advocacy groups from across Asia Pacific, Europe and the United States shared their support for the need to strengthen shared decision-making. On December 7, 2025, the ESMO Asia 2025 Symposium, ‘Advancing EGFRm NSCLC Treatment Through Shared Decision-Making’ highlighted the role of healthcare professionals not only in making sense of the data but also in helping patients and their families navigate complex decision-making.
“High prevalence in Asia of certain NSCLC mutations makes the choice of first-line therapy absolutely critical. Treatment decisions must balance clinical objectives with patient values — weighing disease biology, survival prospects, durable disease control and the tradeoffs of side effects. That’s why shared decision-making is essential: clinicians should present all appropriate treatment options, so the final choice is collaborative and aligned with each patient’s goals,” said Professor Zhu Zhengfei, Director of the Radiation Oncology Department, Fudan University Shanghai Cancer Center.
“When lung cancer patients are empowered to speak up and understand their options, they are more likely to continue the treatment and their dignity is preserved. Initiatives like ‘The 3rd Opinion’ are vital for fostering truly patient-centered partnerships between people living with cancer and their healthcare teams,” noted Ms. Liu Yiting, Marketing & Branding Director, China MeetHealth Mi-Jian Patient Community.
“The shared commitment validates what many people living with lung cancer have long expressed: shared decision making is essential. From our experience supporting patients, meaningful conversations with clinicians help acknowledge patients’ experiences, address their concerns, and preserving their hopes,” added Mr. Jung-Il Cho, Chairman of Korea Lung Cancer Patients Association.
Our commitment comes off the back of a recent patient survey revealing that 90% of Japanese lung cancer patients want to play an active role in their treatment decisions. The survey also found that shared decision-making, where physicians and patients jointly compare treatment options and decide together, is the strongest driver of treatment satisfaction.1
Patient survey finds that those engaged in shared decision-making were 11 times more likely to report higher satisfaction with their treatments, with 90% of lung cancer patients in Japan wanting to play an active role in their treatment decisions. This finding underscores the importance of shared decision-making and patient-centered care.1
To bridge the gap between patients’ desire to engage in shared decision making and their lack of practical support, J&J has launched “J&J withMe”, an online hub that equips lung cancer patients and caregivers with tailored toolkits and conversation guides to prepare for consultations and make informed, personalized treatment decisions.
Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific said, “The 3rd Opinion truly puts patients at the center of care. As part of our deep commitment to address patients’ unmet needs, we will continue partnering with patient advocacy groups and healthcare professionals to help patients to find their voice and the moment when medical advice meets what truly matters to patients.”
In recognition of diverse cultural and clinical norms across Asia Pacific, J&J has also rolled out tailored market activations in collaboration with local patient advocacy groups:
Provision of patient resources such as the “Lung Cancer Book of Answers” in China, ‘Value of Time’ video for patients in Japan, and educational assets in India and Australia/New Zealand;
Digital and social media engagement featuring patients and creators discussing the importance of shared decision-making across Singapore, Malaysia, Philippines, Thailand, and Vietnam;
Event engagement viathe establishment of a patient advisory board in India;
Corporate Social Responsibility program with a lung cancer patient group in Korea, bringing employees and patients together to better understand the disease burden of patients and strengthen emotional support for the patient community.
###
About the 3rd Opinion
“The 3rd Opinion”, the patient’s own opinion, is a new term that sparks a social movement in the lung cancer treatment journey – designed to elevate the patient voice and empower individuals to take an active role in shaping their treatment plan. By prioritizing shared decision-making between patients and healthcare professionals, this collaborative approach ensures that treatment choices are aligned to each patient’s goals, preferences and circumstances. This results in more informed decisions, greater patient satisfaction, and the best possible outcomes.
About Non-Small Cell Lung Cancer
Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.[1], [2] The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.[3] Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.[4] EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.[5], [6],[7],[8],[9],[10] EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.[11] The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent.[12],[13]EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.[14] Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.[15]By comparison, other common cancers, such as breast and prostate cancer have a 5-year real world OS of 90% and 97% respectively[16].
[1] Johnson & Johnson lung cancer patient quantitative survey conducted in Japan, 2025
[2] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.
[3] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.
[4] Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.
[5] Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.
[6] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.
[7] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.
[8] Pennell NA, et al. A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J Clin Oncol. 37:97-104.
[9] Burnett H, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.
[10] Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.
[11] Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911.
[12] American Lung Association. EGFR and Lung Cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr. Accessed March 2025.
[13] Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site.
[14] Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65
[15] Arcila, M. et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013 Feb; 12(2):220-9.
[16] Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.
[17] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, 2024.
Hashtag: #Johnson&Johnson
The issuer is solely responsible for the content of this announcement.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
HONG KONG, Dec. 12, 2025 /PRNewswire/ — As its business footprint expanded, The Hong Kong and China Gas Company Limited (Towngas) decided to modernize its IT infrastructure on the cloud. In collaboration with Amazon Web Services (AWS) and its core partner eCloudvalley, Towngas migrated mission‑critical systems, saving up to 40% in IT costs while ensuring 99.99% availability for core systems.
(From left) Joe Kwok, Hong Kong Country Manager at eCloudvalley; Alex Wong, General Manager of Corporate IT at Towngas
Unwire.pro interviewed Alex Wong, General Manager of Information Technology at Towngas, and Joe Kwok, Regional Manager of eCloudvalley Hong Kong, to explore how cloud modernization drives transformation and how the two organizations are partnering to leverage data and generative AI to deliver better service experiences.
From “Back‑Office Maintenance” to “All‑Around Stewardship”: A Proactive Partnership
Speaking about the collaboration, Joe from eCloudvalley shared: “What we are most proud of in the past two years is that ‘nothing major happened.'” Rather than acting as Towngas’ back‑office support, eCloudvalley functions more like an embedded steward—providing 24/7 monitoring, developing ongoing cost‑optimization strategies, and tailoring every solution to Towngas’ needs.
eCloudvalley oversees full‑spectrum management and alerts—from cloud architecture security and backup mechanisms to cost‑efficiency planning—allowing Towngas’ IT team to focus on business innovation and application development without worrying about infrastructure stability. “eCloudvalley feels like part of our internal team,” said Alex Wong. “They anticipate our needs, optimize costs, and help us achieve maximum return on our AWS investments.”
Reducing IT Costs by 30–40% and Achieving 99.99% Availability — Faster Market Response from Months to Days
With eCloudvalley’s support in modernizing on AWS, Towngas now operates with greater efficiency, agility, and resilience—directly reflected in faster business rollout and scalability. The migration reduced IT costs by 30–40%, cut routine management time, and maintained 99.99% availability for mission‑critical systems, enabling Towngas to deliver consistent and reliable services more rapidly.
After adopting a microservices architecture, Towngas decoupled applications into independently functioning modules, allowing individual feature enhancements without disrupting the whole system. Joe explained that initiatives such as loyalty programs or promotional campaigns can now be adjusted weekly—or even daily—enhancing customer experience and empowering the company with real‑time responsiveness.
Looking Ahead: AI and Security Compliance Take Center Stage
As AI adoption accelerates, Towngas has already begun building AI‑driven services to enhance customer support and streamline operations. For example, leveraging Amazon Bedrock to develop generative AI tools, enabling legal and supply chain teams to quickly validate customer contracts and terms, while also exploring Agentic AI to support employees in handling complex, multi‑step tasks. Joe believes that only when internal processes are optimized and employees learn how to “work with AI” can enterprises effectively apply AI to core decision‑making and business innovation.
Looking ahead, with Hong Kong implementing critical infrastructure regulations by 2026 and AI applications becoming more widespread, data security and regulatory compliance will be top priorities in the partnership. In the AI era, data‑leakage risks take on new forms—so eCloudvalley will continue helping Towngas strengthen protective frameworks, including endpoint security, data governance, and regulation‑aligned backup mechanisms. For enterprises still hesitant about cloud or AI adoption, Joe offers simple advice: start by solving an immediate pain point, build confidence through small‑scale success, and progress step by step toward full transformation.
About eCloudvalley
Founded in 2013, eCloudvalley is a leading cloud service provider in the Asia-Pacific region, serving over 2,400 customers with tailored cloud, data, and security solutions. As an award-winning AWS Premier Partner, the company combines global expertise with local insight to support enterprises through every stage of digital transformation.
– Demonstrates end-to-end expertise in high-performance custom chip design for AI and HPC – Establishes a subsidiary in Japan to strengthen global reach
SEOUL, South Korea, Dec. 12, 2025 /PRNewswire/ — SEMIFIVE, a global leader in custom AI semiconductor (ASIC) design preparing for its KOSDAQ listing, announced today that it has secured multiple AI semiconductor design projects in Japan and recently established its subsidiary in Tokyo, Japan. This move accelerates its global expansion to meet the rapidly increasing demand for Application-Specific Integrated Circuits (ASICs).
These project wins were achieved based on customers’ trust in SEMIFIVE’s accumulated expertise in cutting-edge process nodes, extensive experience in turnkey design for large-die chips, and high-performance ASIC design capabilities based on core IP.
In these newly secured projects, SEMIFIVE is developing high-performance semiconductors for AI and data center applications. Some of these projects will incorporate next-generation technologies such as 3D IC-based advanced packaging, which is expected to improve data-processing efficiency, reduce energy consumption, and increase integration density.
Additionally, SEMIFIVE recently established a subsidiary in Tokyo, strengthening its ability to engage with local customers and manage projects more efficiently. This new subsidiary represents SEMIFIVE’s sixth global location, following its established presence in the United States, China, Vietnam, India, and the Czech Republic. This strategic move is a significant milestone in the company’s global expansion efforts, further solidifying its international network.
“Japan’s semiconductor market is accelerating, fueled by surging demand for high-performance chips, robust government investment, and concerted efforts to build a vibrant AI ecosystem,” said Brandon Cho, CEO and co-founder of SEMIFIVE. “We aim to position Japan as a strategic hub—deepening our technology leadership and collaborating closely with Japanese innovators to drive the AI revolution.”
About SEMIFIVE SEMIFIVE is the pioneer of platform based SoC design, working with customers to implement innovative ideas into custom silicon in the most efficient way. Our SoC platforms offer a powerful springboard for new chip designs and leverage configurable domain-specific architectures and pre-validated key IP pools. We offer comprehensive spec-to-system capabilities with end-to-end solutions so that custom SoCs can be realized faster, with reduced cost and risks for key applications such as data center or AI-enabled IoT. With a strong partnership with Samsung Foundry as a leading SAFE™ DSP partner, as well as the larger ecosystem, SEMIFIVE provides a one-stop shop solution for any SoC design needs. For more information, please visit www.semifive.com.
SEOUL, South Korea, Dec. 12, 2025 /PRNewswire/ — As the global CAD/CAM-based digital prosthetics market continues to grow rapidly, the importance of laboratories equipped with advanced automation and precision manufacturing capabilities is rising. Leaders Dental Laboratory is enhancing its competitiveness in the global digital prosthetics sector through its extensive clinical case experience and its mastery of advanced digital equipment operations.
Specializing in CAD/CAM workflows, Leaders Dental produces high-precision zirconia crowns, bridges, and implant prosthetics based on detailed tooth morphology data. The company integrates data from dental X-rays, intraoral scanners, and CBCT systems, while leveraging automated milling and 3D printing processes alongside case-specific quality control (QC) systems to deliver consistently high-quality digital restorations. Leaders Dental is also widely recognized for its reliable outcomes in complex cases, including full-mouth digital prosthetics, earning strong trust from both domestic and international clients.
To meet the growing global demand for digital prosthetics, Leaders Dental plans to further advance its production automation and AI-driven design systems. Over the next one to two years, the company aims to expand its market share in Korea’s digital prosthetics sector while increasing exports to China and other Asian markets, broadening its overall business portfolio.
TOKYO, Dec. 12, 2025 /PRNewswire/ — The Herbalife Family Foundation (HFF), in partnership with LA Galaxy, hosted an outreach event at the Kobe Jitsugyo Gakuin (KJG) children’s shelter. KJG is one of the nonprofit organizations participating in the Casa Herbalife Program, a global HFF initiative that provides children with access to nutritious meals, educational resources, and safe, nurturing environments.
The event saw four LA Galaxy players including defenders Miki Yamane and Harbor Miller, and midfielders Tucker Lepley and Elijah Wynder who’ve dedicated time in their offseason to this youth engagement event. The team led a fun, skills-based soccer clinic that encouraged the children’s dexterity and coordination. Throughout the energetic afternoon, the players reinforced the power of positive nutrition and aimed to inspire the children to live healthier lives.
“It was an incredible experience to share the joy of soccer with these amazing kids,” said LA Galaxy Defender Miki Yamane. “We hope the activities inspired them to stay active, believe in themselves, and dream big.”
At the end of the game, the players gave away autographed balls, ball caps and sports wristbands to the children. The team also prepared special gifts for a festive exchange, adding warmth to the season of giving.
“At Herbalife Japan, we believe in creating opportunities that inspire and empower children,” said Eri Takemoto, General Manager of Herbalife Japan. “This initiative is more than just a visit— it is about fostering positive role models, encouraging physical activity, and reinforcing our commitment to social responsibility. We hope to instill in the children a stronger sense of self-confidence and belief in their own future,” she added.
Over the past two decades, KJG has helped more than 800 children with HFF grants used for renovations, new equipment, and support for the children’s well-being and development.
In 2025, HFF awarded US$5 million in grants to 165 nonprofit organizations, supporting 200,000 children across 60 countries and territories.
The Herbalife Family Foundation (HFF) is a 501(c)(3) global nonprofit inspired by Herbalife Founder Mark Hughes’ vision to uplift underserved communities. HFF is dedicated to supporting transformative programs that directly enhance children’s well-being, focusing on nutrition and education. Herbalife independent distributors and employees drive the fundraising efforts for HFF. Since 1994, HFF has contributed over $60 million to nonprofit organizations around the world. HFF also actively engages in global relief efforts, responding to communities affected by natural disasters.
For more information, please visit herbalifefamilyfoundation.org and follow us on Instagram and Facebook @Herbalifefamilyfoundation.
About Herbalife Ltd
Herbalife (NYSE: HLF) is a premier health and wellness company, community, and platform that has been changing people’s lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life.
The LA Galaxy are Major League Soccer’s most successful club. Based in Carson, Calif. at Dignity Health Sports Park, the Galaxy have won the MLS Cup a record six times (2002, 2005, 2011, 2012, 2014, 2024), the MLS Supporters’ Shield four times (1998, 2002, 2010, 2011) and the Lamar Hunt U.S. Open Cup twice (2001, 2005), and one Concacaf Champions Cup (2000) since their inception in 1996. Under the direction of LA Galaxy President of Business Operations and Chief Operating Officer Tom Braun and LA Galaxy General Manager Will Kuntz, the Galaxy are the premier club in MLS, with stars like Landon Donovan, David Beckham, Robbie Keane, Steven Gerrard, Zlatan Ibrahimović, Javier Hernandez, Cobi Jones, Riqui Puig, and Marco Reus representing LA over the team’s 30 seasons in MLS. For more information on the LA Galaxy, visit www.lagalaxy.com.
https://www.jnj.com/
